Eagle Pharmaceuticals, Inc

(NASDAQ:EGRX)

Latest On Eagle Pharmaceuticals, Inc (EGRX):

Date/Time Type Description Signal Details
2023-05-10 02:20 ESTNewsEagle Pharmaceuticals, Inc. (EGRX) Q1 2023 Earnings Call TranscriptN/A
2023-05-09 12:39 ESTNewsEagle Pharmaceuticals Non-GAAP EPS of $1.26 beats by $0.27, revenue of $66.3M beats by $2.97MN/A
2023-05-08 23:22 ESTNewsEagle Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-05 21:57 ESTNewsEagle Pharma reaches settlement agreement with Dr. Reddy’s LabN/A
2023-03-13 12:59 ESTNewsEagle Pharmaceuticals Non-GAAP EPS of $1.11 beats by $0.28, revenue of $60.7M misses by $3.56MN/A
2023-03-13 12:58 ESTNewsEagle Pharmaceuticals, Inc. (EGRX) Q4 2022 Earnings Call TranscriptN/A
2023-03-10 22:47 ESTNewsEagle Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-25 16:18 ESTNewsEagle Pharmaceuticals: Upside Could Be Lying Ahead Very NicelyN/A
2023-01-10 22:04 ESTNewsEagle Pharma sets 2023 guidance in line with consensusN/A
2022-11-07 18:11 ESTNewsEagle Pharmaceuticals Non-GAAP EPS of $1.12 beats by $0.21, revenue of $65.9M beats by $3.82MN/A
2022-11-07 18:11 ESTNewsEagle Pharmaceuticals, Inc. (EGRX) Q3 2022 Earnings Call TranscriptN/A
2022-11-04 19:08 ESTNewsEagle Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-10-12 19:50 ESTNewsEagle files for FDA nod to start trial of CAL02 for bacterial pneumoniaN/A
2022-10-03 10:48 ESTNewsEagle, Enalare's ENA-001 for sleep disorder in newborns get FDA orphan drug statusN/A
2022-09-27 10:32 ESTNewsEagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdoseN/A
2022-08-20 00:02 ESTNewsEagle Pharma did not infringe on Endo’s vasopressin patents – appeals courtN/A
2022-08-09 23:38 ESTNewsEagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79MN/A
2022-08-09 23:37 ESTNewsEagle Pharmaceuticals, Inc's (EGRX) CEO Scott Tarriff on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 01:51 ESTNewsEagle Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-01 14:11 ESTNewsEagle/AOP Orphan seek FDA approval of heart disorder therapy landiololN/A
2022-05-10 05:10 ESTNewsEagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 09:14 ESTNewsEagle Pharmaceuticals Non-GAAP EPS of $3.41 misses by $0.25, revenue of $115.9M misses by $7.53MN/A
2022-03-28 21:35 ESTNewsEagle Pharmaceuticals to acquire U.K.-based Acacia PharmaN/A
2022-03-07 19:08 ESTNewsEagle Pharmaceuticals Non-GAAP EPS of $0.85 misses by $0.09, revenue of $42.32M misses by $8.76MN/A
2022-03-07 19:07 ESTNewsEagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-04 22:14 ESTNewsEagle Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-02 01:49 ESTNewsEagle Pharma reports commercial availability of PemfexyN/A
2022-01-05 20:32 ESTNewsEagle provides FY22 business updates; to launch Endo’s Vasostrict generic this monthN/A
2021-12-29 18:55 ESTNewsEagle Pharmaceuticals gets 180 days marketing exclusivity for Endo’s Vasostrict genericN/A
2021-12-21 01:45 ESTNewsEagle Pharma cleared of potential legal hurdle to launch generic for Endo’s VasostrictN/A
2021-12-16 06:08 ESTNewsEagle Pharma wins FDA approval for generic vasopressinN/A
2021-11-10 07:06 ESTNewsEagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tariff on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-09 08:00 ESTNewsEagle Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-09 07:59 ESTNewsEagle Pharmaceuticals EPS misses by $0.27, misses on revenueN/A
2021-09-01 03:06 ESTNewsEagle Pharma surges after favorable court ruling over Endo (updated)N/A
2021-08-25 16:36 ESTNewsEagle Pharma inks licensing deal for CAL02 in severe pneumoniaN/A
2021-08-10 03:15 ESTNewsEagle Pharma in pact with AOP Orphan Pharma for heart disease therapyN/A
2021-08-10 03:14 ESTNewsEagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tariff on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-09 07:01 ESTNewsEagle Pharmaceuticals Q2 2021 Earnings PreviewN/A
2021-08-09 07:00 ESTNewsEagle Pharmaceuticals EPS beats by $0.13, beats on revenueN/A
2021-07-21 06:43 ESTNewsEagle Pharmaceuticals: A Potential Reopening PlayN/A
2021-04-30 10:10 ESTNewsEagle Pharma's Treakisym RTD + rituximab OK'd in Japan for large b-cell lymphomaN/A
2021-03-05 19:38 ESTFinancialsCompany financials have been released.Neutral
2021-03-04 11:30 ESTAnalyst RatingThe Analyst Target Price has decreased from $49.67 to $48.Neutral
2021-03-03 11:32 ESTEarnings EstimateAn EPS average of $3.89 is estimated for the 2022 year.Buy
2021-03-03 11:32 ESTEarnings EstimateAn EPS average of $0.74 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-03 11:32 ESTAnalyst RatingThe Analyst Target Price has decreased from $50 to $49.67.Neutral
2021-03-03 06:08 ESTNewsEagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-02 11:41 ESTNewsEagle Pharmaceuticals EPS beats by $1.16, misses on revenueN/A
2021-02-03 00:55 ESTNewsEagle Pharma receives CRL for its marketing application for vasopressinN/A

About Eagle Pharmaceuticals, Inc (EGRX):

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

EGRX Quotes by TradingView

See Advanced Chart

General

  • Name Eagle Pharmaceuticals, Inc
  • Symbol EGRX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 106
  • Fiscal Year EndDecember
  • IPO Date2014-02-12
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.eagleus.com
View More

Valuation

  • Trailing PE 51.8
  • Forward PE 14.12
  • Price/Sales (Trailing 12 Mt.) 3.31
  • Price/Book (Most Recent Quarter) 3.21
  • Enterprise Value Revenue 2.82
  • Enterprise Value EBITDA 17.64
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $3.28
  • Next Year EPS Estimate $4.02
  • Next Quarter EPS Estimate $0.39
  • Profit Margin 6%
  • Operating Margin 18%
  • Return on Assets 8%
  • Return on Equity 7%
  • Revenue 187.8 million
  • Earnings Per Share $0.87
  • Revenue Per Share $13.93
  • Gross Profit 142.34 million
  • Quarterly Earnings Growth 3.4%
View More

Highlights

  • Market Capitalization 595.7 million
  • EBITDA 36.49 million
  • PE Ratio 4.55
  • PEG Ratio 0.91
  • Analyst Target Price $48
  • Book Value Per Share $14.25
View More

Share Statistics

  • Shares Outstanding 13.22 million
  • Shares Float 10.86 million
  • % Held by Insiders 2224%
  • % Held by Institutions 99.11%
  • Shares Short 1.4 million
  • Shares Short Prior Month 1.3 million
  • Short Ratio 11.9
  • Short % of Float 17%
  • Short % of Shares Outstanding 11%
View More

Technicals

  • Beta 0.62
  • 52 Week High $56.16
  • 52 Week Low $36.31
  • 50 Day Moving Average 46.02
  • 200 Day Moving Average 45.68
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Eagle Pharmaceuticals, Inc (EGRX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Eagle Pharmaceuticals, Inc (EGRX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$N/A$0.96-$0.20592.31%
2020-09-302020-11-02$49.93 million$1.17$0.30296.61%
2020-06-302020-08-10$N/A$0.57$0.24142.55%
2020-03-312020-05-11$46.02 million$0.84$0.5748.02%
2019-12-312020-03-02$48.26 million$0.48$0.49-2.7%
2019-09-302019-11-12$41.15 million$0.26$0.43-39.18%
2019-06-302019-08-08$56.7 million$0.84$0.831.51%
2019-03-312019-05-07$49.79 million$1.01$0.7338.36%
2018-12-312019-02-28$56.05 million$1.20$1.163.63%
2018-09-302018-10-30$51.34 million$1.18$0.9722.15%
2018-06-302018-08-07$59.3 million$0.95$0.8018.45%
2018-03-312018-05-10$46.63 million$0.53$0.69-22.63%
2017-12-312018-02-26$46.79 million$1.00$1.22-18.03%
2017-09-302017-11-08$63.02 million$1.22$0.8740.23%
2017-06-302017-08-09$50.11 million$0.28$0.51-45.1%
2017-03-312017-05-08$76.79 million$1.42$1.420.35%
2016-12-312017-03-01$81.14 million$2.69$3.42-21.25%
2016-09-302016-11-09$37.83 million$0.73$0.6610.06%
2016-06-302016-08-09$40.92 million$0.80$0.7112.28%
2016-03-312016-05-09$29.59 million-$0.17-$0.3044.13%
2015-12-312016-02-25$18.18 million$0.07$0.30-76.86%
2015-09-302015-11-11$5.74 million-$0.65-$0.56-16.07%
2015-06-302015-08-11$6 million-$0.53-$0.577.02%
2015-03-312015-05-12$36.31 million$1.31$1.47-10.88%
2014-12-312015-02-17$5.6 million-$0.47-$0.494.08%
2014-09-302014-12-17$2.81 million-$0.65-$0.49-32.65%
2014-06-302014-08-11$5.79 million-$0.21-$0.3743.24%
2014-03-312014-05-14$5 million-$0.36-$0.26-38.46%

Eagle Pharmaceuticals, Inc (EGRX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A 4.83 million N/A 9.43 million 11.31 million
Income Before Tax N/A 8.93 million N/A -3.01 million 3.36 million
Selling General Administrative N/A 17.7 million N/A 24.76 million 22.46 million
Gross Profit N/A 37.94 million N/A 38.22 million 36.67 million
Ebit N/A 10.79 million N/A -981000 2.9 million
Operating Income N/A 15.42 million N/A 4.04 million 2.9 million
Income Tax Expense 3.33 million N/A 5.63 million N/A 2.35 million
Total Revenue N/A 49.93 million N/A 46.02 million 48.26 million
Cost of Revenue N/A 11.99 million N/A 7.8 million 11.59 million
Total Other Income Expense Net N/A -6.05 million N/A -6.5 million 461000
Net Income From Continuing Operations N/A 7.06 million N/A -2.87 million 1.01 million
Net Income Applicable to Common Shares 8.06 million N/A -256000 -2.87 million 1.01 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -201000 N/A N/A N/A N/A
Change to Liabilities N/A 3.95 million N/A -5.77 million -6.06 million
Total Cash Flow from Investing Activities N/A 96000 -17.97 million -130000 -304000
Net Borrowings N/A -111 million N/A -1000000 -1.25 million
Total Cash Flow from Financial Activities -23.96 million N/A 107.06 million -4.11 million -1.23 million
Change to Operating Activities N/A 4.64 million N/A -2.92 million -7.61 million
Change in Cash -18.53 million N/A 92.24 million -7.44 million 9.08 million
Total Cash from Operating Activities 5.63 million 20.95 million 3.16 million -3.2 million 10.61 million
Depreciation 1.37 million N/A 472000 1.28 million 582000
Other Cash Flow from Investing Activities N/A N/A -17.5 million N/A N/A
Change to Inventory 1.31 million N/A N/A 682000 4.35 million
Change to Account Receivables -5.42 million N/A N/A -3.19 million 15.53 million
Other Cash Flow from Financing Activities N/A N/A -1.28 million -326000 N/A
Change to Net Income N/A 3.12 million N/A 5.51 million 6.13 million
Capital Expenditures 201000 N/A 472000 130000 304000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A 75.37 million N/A 180.11 million 75.38 million
Total Stockholder Equity N/A 172.79 million N/A 181.83 million 179.17 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A 248.16 million N/A 361.94 million 254.55 million
Common Stock 17000 N/A 17000 17000 17000
Other Current Assets N/A 3.67 million N/A 691000 8.57 million
Retained Earnings 84.49 million 76.43 million 69.37 million 69.63 million 72.5 million
Other Liabilities N/A N/A 3.36 million N/A N/A
Other Assets 32.39 million N/A 32.16 million 29.29 million 13.86 million
Cash N/A 89.68 million N/A 202.02 million 109.78 million
Total Current Liabilities 38.09 million 45.51 million N/A 145.88 million 38.82 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 2.08 million N/A 2.12 million 2.42 million 5.92 million
Total Current Assets 166.07 million 163.8 million N/A 275.57 million 179.45 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 133.35 million N/A 129.97 million N/A 123.85 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A 27.02 million N/A 30.78 million 33.56 million
Inventory 8.08 million 6.59 million N/A 8.43 million 6.57 million
Accounts Payable 6.27 million 13.07 million N/A 9.76 million 5.46 million

Eagle Pharmaceuticals, Inc (EGRX) Chart:

Eagle Pharmaceuticals, Inc (EGRX) News:

Below you will find a list of latest news for Eagle Pharmaceuticals, Inc (EGRX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Eagle Pharmaceuticals, Inc (EGRX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50CALL0 0311.54TRUE00
2024-05-1750.35CALL0 106273.32FALSE00
2024-05-177.50.1CALL0 110FALSE00
2024-05-17100.05CALL0 10FALSE00
2024-05-172.50.05PUT0 1310FALSE00
2024-05-1751.2PUT0 44167.92TRUE00
2024-05-177.50PUT0 0400.02TRUE00
2024-05-17100PUT0 0358.75TRUE00
2024-06-212.51.95CALL0 8167.76TRUE00
2024-06-2150.7CALL0 35107.74FALSE00
2024-06-217.50.15CALL0 180FALSE00
2024-06-21100.4CALL0 1040FALSE00
2024-06-2112.50.21CALL0 300FALSE00
2024-06-21150.2CALL0 110FALSE00
2024-06-2117.50.25CALL0 210FALSE00
2024-06-21200.25CALL0 60FALSE00
2024-06-2122.50CALL0 00FALSE00
2024-06-21250.3CALL0 10FALSE00
2024-06-212.50.2PUT0 510FALSE00
2024-06-2151.36PUT0 323111.41TRUE00
2024-06-217.53.2PUT0 1137.2TRUE00
2024-06-21104.9PUT0 1287.68TRUE00
2024-06-2112.50PUT0 0246.55TRUE00
2024-06-21152.9PUT0 1406.45TRUE00
2024-06-2117.50PUT0 0420.17TRUE00
2024-06-21200PUT0 0438.67TRUE00
2024-06-2122.50PUT0 0462.94TRUE00
2024-06-21250PUT0 0314.17TRUE00
2024-09-202.50CALL0 0131.4TRUE00
2024-09-2051.7CALL0 10FALSE00
2024-09-207.51.31CALL0 20FALSE00
2024-09-20100.58CALL0 10FALSE00
2024-09-2012.51CALL0 100FALSE00
2024-09-202.50.2PUT0 100FALSE00
2024-09-2051.3PUT0 4111.15TRUE00
2024-09-207.53.22PUT0 788.77TRUE00
2024-09-20100PUT0 0130TRUE00
2024-09-2012.50PUT0 0240.52TRUE00
2024-12-202.52.1CALL0 1106.5TRUE00
2024-12-2051.04CALL6 595.54FALSE1.040
2024-12-207.50.29CALL6 072.93FALSE0.290
2024-12-20100CALL0 00FALSE00
2024-12-202.50PUT0 00FALSE00
2024-12-2050PUT0 0106.59TRUE00
2024-12-207.50PUT0 0116.45TRUE00
2024-12-20100PUT0 0125TRUE00

Latest EGRX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST1$42.36
Jun 13, 2022 7:59 PM EST59$42.35
Jun 13, 2022 7:59 PM EST19$42.36
Jun 13, 2022 7:59 PM EST20$42.37
Jun 13, 2022 7:59 PM EST15$42.34

Eagle Pharmaceuticals, Inc (EGRX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920077674/0001104659-20-077674-index.htm
2019-11-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/827871/000000000019015809/0000000000-19-015809-index.htm
2019-12-23UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/827871/000000000019016758/0000000000-19-016758-index.htm
2020-02-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/827871/000000000020001613/0000000000-20-001613-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000009375119000292/0000093751-19-000292-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000009375120000571/0000093751-20-000571-index.htm
2018-10-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000021545718006114/0000215457-18-006114-index.htm
2019-01-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000021545719001500/0000215457-19-001500-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/827871/000082787118000005/0000827871-18-000005-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/827871/000082787118000008/0000827871-18-000008-index.htm
2018-11-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/827871/000082787118000010/0000827871-18-000010-index.htm
2019-02-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/827871/000082787119000008/0000827871-19-000008-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/827871/000082787119000013/0000827871-19-000013-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/827871/000082787119000020/0000827871-19-000020-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/827871/000082787119000026/0000827871-19-000026-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/827871/000082787120000007/0000827871-20-000007-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/827871/000082787120000014/0000827871-20-000014-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/827871/000082787120000024/0000827871-20-000024-index.htm
2020-11-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/827871/000082787120000028/0000827871-20-000028-index.htm
2020-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000083423720001678/0000834237-20-001678-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000090571819000233/0000905718-19-000233-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000090571820000237/0000905718-20-000237-index.htm
2019-05-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/827871/000091412119001251/0000914121-19-001251-index.htm
2020-01-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/827871/000091412120000205/0000914121-20-000205-index.htm
2020-09-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000091957420005780/0000919574-20-005780-index.htm
2018-11-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000103342718000044/0001033427-18-000044-index.htm
2019-02-01SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000104018819000014/0001040188-19-000014-index.htm
2018-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/827871/000104746918003351/0001047469-18-003351-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/827871/000104746919002725/0001047469-19-002725-index.htm
2019-11-15S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/827871/000104746919006334/0001047469-19-006334-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/827871/000104746920002708/0001047469-20-002708-index.htm
2018-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/827871/000110465918028560/0001104659-18-028560-index.htm
2018-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918031932/0001104659-18-031932-index.htm
2018-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918033632/0001104659-18-033632-index.htm
2018-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918039299/0001104659-18-039299-index.htm
2018-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918041821/0001104659-18-041821-index.htm
2018-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918044211/0001104659-18-044211-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918049991/0001104659-18-049991-index.htm
2018-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918054242/0001104659-18-054242-index.htm
2018-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918056560/0001104659-18-056560-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918058763/0001104659-18-058763-index.htm
2018-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918060180/0001104659-18-060180-index.htm
2018-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918060181/0001104659-18-060181-index.htm
2018-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918064473/0001104659-18-064473-index.htm
2018-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918064476/0001104659-18-064476-index.htm
2018-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918065262/0001104659-18-065262-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918066805/0001104659-18-066805-index.htm
2018-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465918069984/0001104659-18-069984-index.htm
2018-12-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/827871/000110465918073566/0001104659-18-073566-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919001014/0001104659-19-001014-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000110465919008815/0001104659-19-008815-index.htm
2019-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919009715/0001104659-19-009715-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919011323/0001104659-19-011323-index.htm
2019-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919021218/0001104659-19-021218-index.htm
2019-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/827871/000110465919024853/0001104659-19-024853-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919027293/0001104659-19-027293-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919027294/0001104659-19-027294-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919027656/0001104659-19-027656-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919030938/0001104659-19-030938-index.htm
2019-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919033601/0001104659-19-033601-index.htm
2019-06-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919037022/0001104659-19-037022-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919043842/0001104659-19-043842-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919044694/0001104659-19-044694-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919052391/0001104659-19-052391-index.htm
2019-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919055083/0001104659-19-055083-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919062004/0001104659-19-062004-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919063691/0001104659-19-063691-index.htm
2019-12-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/827871/000110465919069948/0001104659-19-069948-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919070785/0001104659-19-070785-index.htm
2019-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919071175/0001104659-19-071175-index.htm
2019-12-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/827871/000110465919072197/0001104659-19-072197-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919072749/0001104659-19-072749-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919072755/0001104659-19-072755-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919072757/0001104659-19-072757-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919073233/0001104659-19-073233-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465919074048/0001104659-19-074048-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920001786/0001104659-20-001786-index.htm
2020-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920002318/0001104659-20-002318-index.htm
2020-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920002417/0001104659-20-002417-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920003230/0001104659-20-003230-index.htm
2020-01-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000110465920004909/0001104659-20-004909-index.htm
2020-01-29CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/827871/000110465920008226/0001104659-20-008226-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920013526/0001104659-20-013526-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000110465920016417/0001104659-20-016417-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000110465920020710/0001104659-20-020710-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920027475/0001104659-20-027475-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920033624/0001104659-20-033624-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920034363/0001104659-20-034363-index.htm
2020-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920047177/0001104659-20-047177-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920051929/0001104659-20-051929-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/827871/000110465920053416/0001104659-20-053416-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920055848/0001104659-20-055848-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920059088/0001104659-20-059088-index.htm
2020-05-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920063470/0001104659-20-063470-index.htm
2020-05-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/827871/000110465920065382/0001104659-20-065382-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920068496/0001104659-20-068496-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920077674/0001104659-20-077674-index.htm
2020-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920082424/0001104659-20-082424-index.htm
2020-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920084060/0001104659-20-084060-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920091548/0001104659-20-091548-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920092370/0001104659-20-092370-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920104607/0001104659-20-104607-index.htm
2020-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920107555/0001104659-20-107555-index.htm
2020-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920108097/0001104659-20-108097-index.htm
2020-09-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920109144/0001104659-20-109144-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920110681/0001104659-20-110681-index.htm
2020-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000110465920120251/0001104659-20-120251-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919118041189/0001209191-18-041189-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119002391/0001209191-19-002391-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005439/0001209191-19-005439-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005440/0001209191-19-005440-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005441/0001209191-19-005441-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005442/0001209191-19-005442-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005443/0001209191-19-005443-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005444/0001209191-19-005444-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005445/0001209191-19-005445-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005446/0001209191-19-005446-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005447/0001209191-19-005447-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119005454/0001209191-19-005454-index.htm
2019-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119007134/0001209191-19-007134-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119015645/0001209191-19-015645-index.htm
2019-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119017385/0001209191-19-017385-index.htm
2019-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119017389/0001209191-19-017389-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119023147/0001209191-19-023147-index.htm
2019-09-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119048554/0001209191-19-048554-index.htm
2019-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919119052905/0001209191-19-052905-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120002339/0001209191-20-002339-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120002341/0001209191-20-002341-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120002343/0001209191-20-002343-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120002345/0001209191-20-002345-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120002347/0001209191-20-002347-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120002350/0001209191-20-002350-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120002353/0001209191-20-002353-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120002356/0001209191-20-002356-index.htm
2020-01-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120002360/0001209191-20-002360-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120004986/0001209191-20-004986-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120004987/0001209191-20-004987-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120004988/0001209191-20-004988-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120004990/0001209191-20-004990-index.htm
2020-11-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120056467/0001209191-20-056467-index.htm
2020-11-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000120919120056469/0001209191-20-056469-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000127417319000046/0001274173-19-000046-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/827871/000127417320000023/0001274173-20-000023-index.htm
2019-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000141057819001006/0001410578-19-001006-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000141057819001554/0001410578-19-001554-index.htm
2019-10-118-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/827871/000141057819001626/0001410578-19-001626-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000156761919010640/0001567619-19-010640-index.htm
2019-09-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000156761919018305/0001567619-19-018305-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000156761919018534/0001567619-19-018534-index.htm
2019-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000156761919019404/0001567619-19-019404-index.htm
2019-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000156761919019579/0001567619-19-019579-index.htm
2019-10-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000156761919019765/0001567619-19-019765-index.htm
2019-10-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000156761919019950/0001567619-19-019950-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/827871/000156761919020068/0001567619-19-020068-index.htm
2019-12-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/827871/999999999519002823/9999999995-19-002823-index.htm

Eagle Pharmaceuticals, Inc (EGRX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eagle Pharmaceuticals, Inc (EGRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2224%
Institutional Ownership: 9911%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-03-05SANDER A FLAUMDirectorBuy2,340.004.049,453.6013,714.00https://www.sec.gov/Archives/edgar/data/827871/000120919119017385/0001209191-19-017385-index.htm
2019-04-01Scott TarriffCEOSell24,975.0050.151,252,496.251,500,202.00https://www.sec.gov/Archives/edgar/data/827871/000120919119023147/0001209191-19-023147-index.htm
2019-01-03Scott TarriffCEOSell302.0040.5712,252.141,518,390.00https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/0001209191-19-002391-index.htm
2019-01-03Scott TarriffCEOSell5,670.0039.70225,099.001,518,692.00https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/0001209191-19-002391-index.htm
2019-01-03Scott TarriffCEOSell10,597.0039.04413,706.881,524,362.00https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/0001209191-19-002391-index.htm
2019-03-01Scott TarriffCEOSell12,428.0051.81643,894.681,525,177.00https://www.sec.gov/Archives/edgar/data/827871/000120919119015645/0001209191-19-015645-index.htm
2019-01-02Scott TarriffCEOSell8,500.0040.03340,255.001,534,959.00https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/0001209191-19-002391-index.htm
2019-03-01Scott TarriffCEOSell12,000.0050.51606,120.001,537,605.00https://www.sec.gov/Archives/edgar/data/827871/000120919119015645/0001209191-19-015645-index.htm
2019-01-02Scott TarriffCEOSell6,500.0039.30255,450.001,543,459.00https://www.sec.gov/Archives/edgar/data/827871/000120919119002391/0001209191-19-002391-index.htm
2019-02-01Scott TarriffCEOSell900.0042.3038,070.001,549,605.00https://www.sec.gov/Archives/edgar/data/827871/000120919119007134/0001209191-19-007134-index.htm
2018-06-28Scott TarriffCEOBuy124,804.004.04504,208.161,549,959.00https://www.sec.gov/Archives/edgar/data/827871/000120919118041189/0001209191-18-041189-index.htm
2019-02-01Scott TarriffCEOSell29,185.0041.521,211,761.201,550,505.00https://www.sec.gov/Archives/edgar/data/827871/000120919119007134/0001209191-19-007134-index.htm
2020-01-05Scott TarriffCEOBuy58,300.001,558,502.00https://www.sec.gov/Archives/edgar/data/827871/000120919120002360/0001209191-20-002360-index.htm
2019-01-23Scott TarriffCEOBuy61,300.001,579,690.00https://www.sec.gov/Archives/edgar/data/827871/000120919119005447/0001209191-19-005447-index.htm
2019-03-04STEVEN B RATOFFDirectorBuy2,340.004.049,453.6018,004.00https://www.sec.gov/Archives/edgar/data/827871/000120919119017389/0001209191-19-017389-index.htm
2019-01-23Pete A. MeyersChief Financial OfficerBuy19,300.0026,400.00https://www.sec.gov/Archives/edgar/data/827871/000120919119005444/0001209191-19-005444-index.htm
2019-01-23Adrian HepnerEVP and Chief Medical OfficerBuy19,000.0027,229.00https://www.sec.gov/Archives/edgar/data/827871/000120919119005443/0001209191-19-005443-index.htm
2019-01-23David PernockPres. & Chief Comm. OfficerBuy20,900.0031,008.00https://www.sec.gov/Archives/edgar/data/827871/000120919119005445/0001209191-19-005445-index.htm
2020-01-05Pete A. MeyersChief Financial OfficerBuy19,500.0045,900.00https://www.sec.gov/Archives/edgar/data/827871/000120919120002347/0001209191-20-002347-index.htm
2020-01-05Adrian HepnerEVP and Chief Medical OfficerBuy24,000.0051,229.00https://www.sec.gov/Archives/edgar/data/827871/000120919120002345/0001209191-20-002345-index.htm
2020-01-05David PernockPres. & Chief Comm. OfficerBuy21,500.0052,508.00https://www.sec.gov/Archives/edgar/data/827871/000120919120002350/0001209191-20-002350-index.htm
2019-10-25Executive Capital LP HudsonDirectorSell15,437.0063.57981,302.30732,777.00https://www.sec.gov/Archives/edgar/data/827871/000156761919020068/0001567619-19-020068-index.htm
2019-10-24Executive Capital LP HudsonDirectorSell1,494.0062.5393,412.50748,214.00https://www.sec.gov/Archives/edgar/data/827871/000156761919020068/0001567619-19-020068-index.htm
2019-10-23Executive Capital LP HudsonDirectorSell200.0062.5812,516.00749,708.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019950/0001567619-19-019950-index.htm
2019-10-22Executive Capital LP HudsonDirectorSell6,567.0062.68411,617.59749,908.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019950/0001567619-19-019950-index.htm
2019-10-21Executive Capital LP HudsonDirectorSell3,849.0062.56240,790.75756,475.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019950/0001567619-19-019950-index.htm
2019-10-18Executive Capital LP HudsonDirectorSell1,600.0062.61100,174.08760,324.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019765/0001567619-19-019765-index.htm
2019-10-17Executive Capital LP HudsonDirectorSell13,842.0062.58866,196.37761,924.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019765/0001567619-19-019765-index.htm
2019-10-16Executive Capital LP HudsonDirectorSell102.0062.506,375.00775,766.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019765/0001567619-19-019765-index.htm
2019-10-15Executive Capital LP HudsonDirectorSell3,909.0062.63244,835.92775,868.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019579/0001567619-19-019579-index.htm
2019-10-11Executive Capital LP HudsonDirectorSell16,300.0060.39984,418.94779,777.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019579/0001567619-19-019579-index.htm
2019-10-10Executive Capital LP HudsonDirectorSell7,829.0060.16471,002.03796,077.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019579/0001567619-19-019579-index.htm
2019-10-08Executive Capital LP HudsonDirectorSell1,558.0060.0393,519.73803,906.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019404/0001567619-19-019404-index.htm
2019-10-07Executive Capital LP HudsonDirectorSell4,901.0060.11294,599.60805,464.00https://www.sec.gov/Archives/edgar/data/827871/000156761919019404/0001567619-19-019404-index.htm
2019-09-17Executive Capital LP HudsonDirectorSell100.0060.006,000.00810,365.00https://www.sec.gov/Archives/edgar/data/827871/000156761919018534/0001567619-19-018534-index.htm
2019-09-12Executive Capital LP HudsonDirectorSell200.0060.0712,014.00810,465.00https://www.sec.gov/Archives/edgar/data/827871/000156761919018305/0001567619-19-018305-index.htm
2019-09-11Executive Capital LP HudsonDirectorSell1,112.0060.0666,784.94810,665.00https://www.sec.gov/Archives/edgar/data/827871/000156761919018305/0001567619-19-018305-index.htm
2019-05-10Douglas L BraunsteinDirectorSell100,000.0056.145,614,000.00811,777.00https://www.sec.gov/Archives/edgar/data/827871/000156761919010640/0001567619-19-010640-index.htm
2019-05-09Douglas L BraunsteinDirectorSell59,223.0057.953,431,972.85911,777.00https://www.sec.gov/Archives/edgar/data/827871/000156761919010640/0001567619-19-010640-index.htm